Oppenheimer Keeps Their Buy Rating on Tabula Rasa HealthCare (TRHC)

Oppenheimer analyst Mohan Naidu reiterated a Buy rating on Tabula Rasa HealthCare (TRHC) today and set a price target of $97. The company’s shares closed on Tuesday at $72.38.

Naidu wrote:

“Tabula Rasa’s unique services to improve Rx regimens and reduce/eliminate adverse drug events are gaining traction, and the positive data points out of several pilots (CMMI, Landmark) are likely to push TRHC to the forefront in making personalized medicine a reality. The scientific process of analyzing multi-drug interactions for each specific patient is unique and is the culmination of several years of R&D that we believe will be hard to replicate. Domestically, the push to grow PACE program membership to 200K by 2028, traction with Medicare and very encouraging pilot results set the road for TRHC very well, while international opportunities are no fewer. ANF Portugal is a testing ground, and the positive results will provide a roadmap in other countries. Reiterate Outperform, $97 target.”

According to TipRanks.com, Naidu is a 5-star analyst with an average return of 15.3% and a 61.6% success rate. Naidu covers the Services sector, focusing on stocks such as Tivity Health Inc, Hms Holdings Corp, and Express Scripts.

Currently, the analyst consensus on Tabula Rasa HealthCare is a Strong Buy with an average price target of $90.17, implying a 24.6% upside from current levels. In a report issued on December 3, Cantor Fitzgerald also reiterated a Buy rating on the stock with a $99 price target.


See today’s analyst top recommended stocks >>

The company has a one-year high of $91.16 and a one-year low of $27.25. Currently, Tabula Rasa HealthCare has an average volume of 335.4K.

Based on the recent corporate insider activity of 82 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of TRHC in relation to earlier this year.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Tabula Rasa Healthcare, Inc. engages in the development of pharmaceutical software that optimizes medication regimens. It offers cloud-based applications, such as EireneRx and MedWise Advisor. The company was founded by Calvin H. Knowlton and Orsula V. Knowlton in April 2009 and is headquartered in Moorestown, NJ.